Hassan, Raffit http://orcid.org/0000-0002-4012-3633
Butler, Marcus http://orcid.org/0000-0002-9840-7057
O’Cearbhaill, Roisin E. http://orcid.org/0000-0001-8217-4554
Oh, David Y.
Johnson, Melissa http://orcid.org/0000-0001-9874-1314
Zikaras, Kevin
Smalley, Munisha
Ross, Michael
Tanyi, Janos L.
Ghafoor, Azam
Shah, Nirali N. http://orcid.org/0000-0002-8474-9080
Saboury, Babak http://orcid.org/0000-0002-8632-6292
Cao, Liang http://orcid.org/0000-0001-7293-8338
Quintás-Cardama, Alfonso http://orcid.org/0000-0002-4623-8917
Hong, David http://orcid.org/0000-0001-8721-1609
Article History
Received: 3 January 2023
Accepted: 8 June 2023
First Online: 27 July 2023
Change Date: 21 July 2023
Change Type: Update
Change Details: In the version of this article initially published, the ClinicalTrials.gov ID was not included in the Abstract and is now amended in the HTML and PDF versions of the article.
Competing interests
: R.H. has received funding from the Intramural Research Program of the National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (ZIA-BC-010816) and has received funding for conduct of clinical trials via a cooperative research and development agreement between NCI and Bayer AG and TCR<sup>2</sup> Therapeutics. D.Y.O. is supported by NIH K08AI139375, a Young Investigator Award from the Prostate Cancer Foundation and the Damon Runyon Clinical Investigator Award (110-21); has received research support from Merck, PACT Pharma, the Parker Institute for Cancer Immunotherapy, Poseida Therapeutics, Roche/Genentech and Nutcracker Therapeutics; and has received travel/accommodations from Roche/Genentech. M.J. has received research funding, all payments made to the institution, from AbbVie, Acerta, Adaptimmune, Amgen, Apexigen, Arcus Biosciences, Array BioPharma, Artios Pharma, AstraZeneca, Atreca, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Calithera Biosciences, Carisma Therapeutics, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Dynavax, Eli Lilly, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences, Immunocore, Impact, Incyte, Janssen, Kadmon Pharmaceuticals, Kartos Therapeutics, Loxo Oncology, Lycera, Memorial Sloan Kettering Cancer Center, Merck, Merus, Mirati Therapeutics, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, Nuvalent, OncoMed Pharmaceuticals, Palleon Pharmaceuticals, Pfizer, PMV Pharmaceuticals, Rain Therapeutics, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals/Birdie Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Stem CentRx, Syndax Pharmaceuticals, Takeda Pharmaceuticals, Tarveda, TCR<sup>2</sup> Therapeutics, Tempest Therapeutics, Tizona Therapeutics, TMUNITY Therapeutics, Turning Point Therapeutics, the University of Michigan, Vyriad and Y-mAbs Therapeutics. M.J. has a consulting/advisory role, all payments made to the institution, with AbbVie, Amgen, Astellas, AstraZeneca, Axelia Oncology, Black Diamond, Calithera Biosciences, Checkpoint Therapeutics, CytomX Therapeutics, Daiichi Sankyo, EcoR1, Editas Medicine, Eisai, Roche/Genentech, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Ideaya Biosciences, iTeos, Janssen, Eli Lilly, Merck, Mirati Therapeutics, Molecular Axiom, Novartis, Oncorus, Pyramid Biosciences, Regeneron Pharmaceuticals, Revolution Medicines, Ribon Therapeutics, Sanofi-Aventis, Takeda Pharmaceuticals, Turning Point Therapeutics and VBL Therapeutics. K.Z., M.S., M.R. and A.Q.-C. are employed by TCR<sup>2</sup> Therapeutics and received stock options as a condition of employment. D.H. has received research grants paid to the institution from AbbVie, Adaptimmune, Adlai Nortye, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Deciphera, Endeavor, Erasca, F. Hoffmann-La Roche, Fate Therapeutics, Genentech, Genmab, Immunogenesis, Infinity, Merck, Mirati Therapeutics, Navier, NCT-CTEP, Novartis, Numab, Pfizer, Pyramid Bio, Revolution Medicine, SeaGen, STCube, Takeda, TCR<sup>2</sup> Therapeutics, Turning Point Therapeutics and VM Oncology. D.H. has a consultant/advisory role (personal) with Acuta, Adaptimmune, Alkermes, Alpha Insights, Amgen, Aumbiosciences, Axiom, Baxter, Bayer, Boxer Capital, BridgeBio, COG, COR2ed, Cowen, Ecor1, Erasca, F. Hoffmann-La Roche, Genentech, Gennao Bio, Gilead, GLG, Group H, Guidepoint, HCW Precision Oncology, Immunogenesis, Janssen, Liberium, MedaCorp, Medscape, Numab, Oncologia Brasil, ORI Capital, Pfizer, Pharma Intelligence, POET Congress, Prime Oncology, Rain Therapeutics, SeaGen, STCube, Takeda, Tavistock, Trieza Therapeutics, Turning Point Therapeutics, WebMD, YingLing Pharma and Ziopharm. D.H. receives support for attending meetings and/or travel from the American Association for Cancer Research, the American Society of Clinical Oncology, Bayer, Genmab, SITC and Telperian. He has stock or stock options from Molecular Match, OncoResponse and Telperian. M.B., R.O.C. and J.L.T. report having received research support from TCR<sup>2</sup> Therapeutics for the conduct of the present trial. A.G., N.N.S., B.S. and L.C. declare no conflicts of interest.